1-3 of 3
Silvia Thoene, MSc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sorafenib and Nilotinib Are Candidates to Overcome Imatinib Resistance in Myeloproliferation with FIP1L1-PDGFRA.

Nikolas von Bubnoff, MD, Sivahari P Gorantla, MSc, Richard A. Engh, PhD, Taiana de Oliveira, PhD, Silvia Thoene, MSc, Espen Åberg, PhD, Christian Peschel, MD, Justus Duyster, MD
Journal: Blood
Blood (2009) 114 (22): 2912.
https://doi.org/10.1182/blood.V114.22.2912.2912
Published: 2009
Journal Articles

Cdx4 Differs from Cdx2 in Its Oncogenic Potential and Its Regulation of Hox Gene Expression in the Murine Bone Marrow Transplantation Model.

Silvia Thoene, MSc, Vijay P.S. Rawat, PhD, Vegi M. Naidu, MSc, Wolfgang Hiddemann, MD, Michaela Feuring-Buske, MD, Christian Buske, MD
Journal: Blood
Blood (2008) 112 (11): 1187.
https://doi.org/10.1182/blood.V112.11.1187.1187
Published: 2008
Journal Articles

The Leukemogenic Potential of Cdx2 Is Dependent on Its N-Terminal Serine Sites and Can Be Counteracted by MAPK Inhibitors

Vijay P.S. Rawat, PhD, Vegi M. Naidu, MSc, Deepak Bararia, PhD, Silvia Thoene, MSc, Farid Ahmed, PhD, Leticia Quintanilla-Martinez, MD, Wolfgang Hiddemann, Stefan Bohlander, Michaela Feuring-Buske, MD, Christian Buske, MD
Journal: Blood
Blood (2008) 112 (11): 3784.
https://doi.org/10.1182/blood.V112.11.3784.3784
Published: 2008